FDA accepts IND application for OX640 epinephrine nasal powder
The FDA accepted an investigational new drug application for the epinephrine intranasal powder OX640 for treating anaphylaxis, according to a press release from Orexo.
“Although epinephrine is well established as a treatment, significant challenges remain with today’s injection-based products,” Nikolaj Sørensen, MSc, president and CEO of Orexo, said in the release.
The limitations of current epinephrine autoinjectors per the release include fear of needles, use errors, and storage and shelf-life challenges. Data included in the investigational new drug application for OX640 (extensive